Obesity treatment market fragmenting, forecast by 2019

With the recent FDA approval of the obesity drugs Qsymia (Vivus) and Lorcaserin (Arena) this year, the global market for the treatment of obesity, which has been largely represented by Lap-Band and other devices, will start to fragment with a growing number of drug and device treatment options vying for the growing worldwide market. Treatments for obesity now fall into to device and drug categories, each of which has sub-types:

Obesity Device Types

  • Appetite suppression
  • Gastric emptying
  • Malabsorption
  • Artificial fullness

Obesity Drug Types

  • Satiety
  • Malabsorption
  • Appetite suppression
  • Combination drugs

Consequently, we forecast by 2019 that the market will look very different from how it does currently (roughly evenly split between artificial fullness devices, malabsorption drugs, and appetite suppression drugs). By 2019, multiple drug and device types will hold meaningful shares of the growing global market.  The dominant treatment option will be combination drugs, such as the still-pending Contrave, which is a combination of naltrexone SR (sustained release) and bupropion SR.

Below is illustrated the shares by treatment type for the global market in obesity treatment:

Source: MedMarket Diligence, LLC; Report #S835, “Products, Technologies and Markets Worldwide for the Clinical Management of Obesity, 2011-2019″.

Leave a Reply